Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

22.07.25 17:15 Uhr

Werte in diesem Artikel
Aktien

162,02 EUR 2,90 EUR 1,82%

76,50 EUR 0,00 EUR 0,00%

Indizes

6.309,6 PKT 4,0 PKT 0,06%

Danaher Corporation’s DHR second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of $1.64. The bottom line increased 4.7% year over year.Danaher reported net sales of $5.94 billion, which beat the consensus estimate of $5.84 billion. The metric increased 3.5% year over year, driven by impressive performance of all the segments.DHR’s core sales increased 1.5% year over year in the quarter. Foreign-currency translations had a positive impact of 2%.DHR’s Segmental DiscussionRevenues from the Life Sciences segment totaled $1.78 billion, up 0.5% year over year. We expected the segment’s revenues to be $1.71 billion. However, core sales decreased 2.5% year over year. Acquisitions/divestitures had a positive impact of 1.5% on segmental sales while foreign-currency translations also had a positive impact of 1.5%. Operating loss was $239 million against operating profit of $233 million in the year-ago quarter. Revenues from the Diagnostics segment totaled $2.31 billion, up 2% year over year. Our estimate for revenues was $2.29 billion. Core sales increased 2% year over year, while foreign currency had a positive impact of 0.5% on sales. However, acquisitions/divestitures impacted sales by 0.5%. Operating profit was $554 million, down 0.4% on a year-over-year basis.Revenues from the Biotechnology segment totaled $1.85 billion, up 8% year over year. Our estimate was $1.83 billion. Core sales increased 6% year over year while foreign-currency translations had a positive impact of 2%. Operating profit was $531 million, up 14.9% year over year.Danaher Corporation Price, Consensus and EPS Surprise Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation QuoteDanaher’s Margin ProfileIn the second quarter, Danaher’s cost of sales increased 4.2% year over year to $2.41 billion. Gross profit of $3.52 billion increased 2.8% year over year. The gross margin was 59.3% compared with 59.7% in the year-ago quarter.Selling, general and administrative expenses of $2.36 billion recorded an increase of 26.3% on a year-over-year basis. Research and development expenses were $403 million, up 3.1% year over year.Danaher’s operating profit decreased 34.9% year over year to $760 million. Operating margin contracted to 12.8% from 20.3% in the year-ago quarter.DHR’s Balance Sheet and Cash FlowExiting the second quarter, DHR had cash and equivalents of $2.96 billion compared with $2.1 billion at 2024-end. Long-term debt was $16.9 billion at the end of the quarter compared with $15.5 billion at the end of December 2024.Danaher generated net cash of $2.64 billion from operating activities in the first six months of 2025 compared with $3.16 billion in the previous year’s comparable period. Capital expenditures totaled $493 million in the same period, down 14.7% year over year. Adjusted free cash flow decreased 16.5% year over year to $2.15 billion in the first six months of 2025.In the same period, DHR paid out dividends of $423 million, up 12.2% on a year-over-year basis.Danaher’s OutlookFor the third quarter, Danaher expects adjusted core sales from continuing operations to increase in the low single digits on a year-over-year basis.The metric is anticipated to increase approximately 3% on a year-over-year basis in 2025. The company expects adjusted earnings to be $7.70-$7.80 per share compared with $7.60-$7.75 expected earlier.DHR’s Zacks RankThe company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other CompaniesQuest Diagnostics Inc.’s DGX second-quarter 2025 adjusted earnings per share (EPS) of $2.62 beat the Zacks Consensus Estimate by 1.9%. The metric also exceeded the year-ago adjusted figure by 11.5%.Revenues reported in the second quarter rose 15.2% year over year to $2.76 billion. The metric surpassed the Zacks Consensus Estimate by 1.5%.Tenet Healthcare Corporation THC reported earnings of $4.02 per share in the second quarter of 2025, beating the Zacks Consensus Estimate of $2.84. This compares with earnings of $2.31 per share a year ago.The company posted revenues of $5.27 billion in the quarter, surpassing the Zacks Consensus Estimate by 2.43%. This compares with year-ago revenues of $5.1 billion. Medpace Holdings, Inc. MEDP came out with quarterly earnings of $3.1 per share in the second quarter of 2025, beating the Zacks Consensus Estimate of $3 per share. This compares with earnings of $2.75 per share a year ago.Medpace posted revenues of $603.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.48%. This compares with year-ago revenues of $528.1 million.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report Tenet Healthcare Corporation (THC): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Danaher und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Danaher

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Danaher

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Danaher Corp.

Wer­bung

Analysen zu Danaher Corp.

DatumRatingAnalyst
19.07.2019Danaher BuyNeedham & Company, LLC
30.05.2019Danaher OutperformWolfe Research
17.04.2019Danaher BuyNeedham & Company, LLC
28.02.2019Danaher BuyNeedham & Company, LLC
03.01.2019Danaher BuyNeedham & Company, LLC
DatumRatingAnalyst
19.07.2019Danaher BuyNeedham & Company, LLC
30.05.2019Danaher OutperformWolfe Research
17.04.2019Danaher BuyNeedham & Company, LLC
28.02.2019Danaher BuyNeedham & Company, LLC
03.01.2019Danaher BuyNeedham & Company, LLC
DatumRatingAnalyst
21.04.2017Danaher Sector PerformRBC Capital Markets
27.05.2016Danaher Sector PerformRBC Capital Markets
22.04.2016Danaher Sector PerformRBC Capital Markets
27.01.2016Danaher Sector PerformRBC Capital Markets
23.10.2015Danaher Sector PerformRBC Capital Markets
DatumRatingAnalyst
14.12.2006Danaher underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Danaher Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen